Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 122% leap this year.
Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend.
Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak," Scangos said in an interview.